Skip to main content

Table 3 Multivariate analysis of prognostic factors for overall survival and progression-free survival

From: Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study

Factor OS   PFS
HR P Value   HR P Value
Sex (female vs. male) 0.976 0.925   0.668 0.156
Age 1.01 0.229   1.011 0.189
Mean tumor diameter (cm) 1.02 0.572   1.003 0.932
Albumin g/dL 1.002 0.915   1.053 0.027
Total bilirubin u mol/L 1.008 0.45   1.012 0.239
AFP > 400 ng/mL 1.755 0.006   1.456 0.082
BCLC B 1.563 0.109   0.28 0.104
Hepatitis B 0.898 0.737   0.433 0.012
TACE-RFA 0.461 0   0.213 < 0.001
  1. OS overall survival, PFS progression-free survival, HR hazard ratio, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, RFA radiofrequency ablation, TACE transarterial chemoembolization